A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: RO7497372
- Registration Number
- NCT06847854
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 176
- Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the world health organization (WHO) and/or American Diabetes Association
- Participant consents to AH collection
- Collection of > 90 microlitres (µL) AH (at each visit required per schedule of activities [SoA]) if deemed feasible and safe by the Investigator.
- Macular thickening secondary to DME involving the center of the fovea with CST >= 325 µm at screening
- Decreased BCVA primarily due to DME with ETDRS score of 78 to 19 letters (both inclusive) at screening
- Adequately clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images
- Diagnosis of non-proliferative DR
- Treatment-naive and Pre-treated participants after washout
- Any major illness or major surgical procedure ≤ 4 weeks before Day 1
- Any febrile illness and associated sequelae ≤ 1 week prior to Day 1
- Active cancer ≤ 1 year prior to Day 1
- Cerebral vascular accident (including stroke and transient ischemic attack) or myocardial infarction ≤ 24 weeks prior to Day 1
- HbA1c ≥ 12% at screening
- Any panretinal photocoagulation or macular laser photocoagulation treatment prior to Day 1
- History of vitreoretinal surgery/pars plana vitrectomy
- Any cataract surgery within 12 weeks prior to Day 1 or any planned surgery during the study
- History of any glaucoma surgery including laser glaucoma procedures
- Uncontrolled glaucoma
- Any active intra- or periocular infection on Day 1
- Any active or history of Intraocular inflammation
- Intravitreal treatment with an anti-IL-6 (e.g., vamikibart) or anti-IL-6 receptor treatment at any time
- Any proliferative DR
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Part 1: Multiple Ascending Dose RO7497372 Participants will receive multiple ascending doses of RO7497372, 3 times every 4 weeks (Q4W) as an IVT injection up to Week 8 in the study eye. Part 2: RO7497372 Low Dose RO7497372 Participants will receive 6 doses of RO7497372, low dose, Q4W followed by 3 doses, every eight weeks (Q8W) as an IVT injection up to Week 44 in the study eye. Part 2: RO7497372 High Dose RO7497372 Participants will receive 6 doses of RO7497372, high dose, Q4W followed by 3 doses, Q8W as an IVT injection up to Week 44 in the study eye.
- Primary Outcome Measures
Name Time Method Part 1: Number of Participants With Adverse Events (AEs) Up to 28 Weeks Part 2: Number of Participants With Intraocular Inflammation (IOI) AEs as Reported by the Investigator Baseline to Week 48 Part 2: Number of Participants With Severe or Serious Drug-Related IOI AEs Baseline to Week 48 Number of participants with severe or serious drug-related IOI AEs severity will be determined according to the DAIDS toxicity grading scale as reported by the Investigator.
Part 2: Number of Participants With Occlusive Retinal Vasculitis AEs as Reported by the Investigator Baseline to Week 48
- Secondary Outcome Measures
Name Time Method Part 1: Concentration of RO7497372 in Blood Up to Week 28 Part 1: Concentration of RO7497372 in Aqueous Humor (AH) Up to Week 28 Part 2: Number of Participants With AEs Up to 56 weeks Number of participants with AEs severity determined according to the DAIDS toxicity grading scale.
Part 2: Number of Participants With Persistent Treatment-induced Anti-drug Antibody (ADAs) Up to 56 weeks Part 2: Concentration of RO7497372 in AH Up to Week 56 Part 2: Concentration of RO7497372 in Plasma Up to Week 56 Part 2: Change From Baseline in Best Corrected Visual Acuity (BCVA) Score Over Time From Baseline (Day 1) up to Week 56 BCVA will be measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Part 2: Absolute Value of BCVA Score Over Time Up to Week 56 BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Part 2: Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time Up to Week 56 BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Part 2: Percentage of Participants Avoiding a Loss of ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA From Baseline Over Time Up to Week 56 BCVA will be measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision VisionTM or lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The range of EDTRS is 0 to 100 letters. Higher scores indicates improvement in VA.
Part 2: Change From Baseline in Central Subfield Thickness (CST) Over Time From Baseline (Day 1) up to Week 56 CST is defined as the average thickness of the central 1-mm circle of the ETDRS grid centered to the fovea measured between the internal limiting membrane and the Bruch's membrane. CST will be determined by CRC evaluation of SD-OCT images.
Part 2: Absolute Value of CST Over Time Up to Week 56 CST is defined as the average thickness of the central 1-mm circle of the ETDRS grid centered to the fovea measured between the internal limiting membrane and the Bruch's membrane. CST will be determined by CRC evaluation of SD-OCT images.
Part 2: Percentage of Participants With Absence of DME Over Time Up to Week 56 Absence of DME is defined as CST \< 325 micrometre (μm) by spectral domain optical coherence tomography (SD-OCT).
Part 2: Percentage of Participants With Absence of Intraretinal Fluid and/or Subretinal Fluid Over Time Up to Week 56 Presence of intraretinal and subretinal fluid will be determined by CRC evaluation of SD -OCT images.
Part 2: Percentage of Participants With ≥ 2-step Diabetic Retinopathy Severity Scale (DRSS) Improvement From Baseline on the ETDRS DRSS Over Time Up to Week 56 The DRSS will be graded according to ETDRS grading schedules from report 18 JOVS, February 1998, Vol. 39, No. 2. ETDRS DRSS is 13 step scale which measures severity of diabetic retinopathy (DR). The DRSS scores vary from 10 (DR absent) to 90 (ungradable proliferative diabetic retinopathy(PDR)). Higher levels indicate higher severity.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (14)
Retinal Consultants of AZ, Ltd
🇺🇸Peoria, Arizona, United States
Associated Retina Consultants
🇺🇸Phoenix, Arizona, United States
Retinal Consultants Medical Group
🇺🇸Modesto, California, United States
Bay Area Retina Associates
🇺🇸Walnut Creek, California, United States
Florida Eye Associates
🇺🇸Melbourne, Florida, United States
Cumberland Valley Retina PC
🇺🇸Hagerstown, Maryland, United States
Retina Associates of Michigan
🇺🇸Grand Blanc, Michigan, United States
Ross Eye Institute
🇺🇸Buffalo, New York, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
Erie Retinal Surgery
🇺🇸Erie, Pennsylvania, United States
Austin Clinical Research LLC
🇺🇸Austin, Texas, United States
Retina Consultants of Texas
🇺🇸The Woodlands, Texas, United States
Spokane Eye Clinical Research
🇺🇸Spokane, Washington, United States
Emanuelli Research and Development Center
🇵🇷Arecibo, Puerto Rico